Abstract
Genome sequencing (GS) is increasingly being translated into clinical practice and is a technology characterized by a complex multi-step workflow. Funding decisions for GS would be aided by formal economic evaluation of GS platforms, but these analyses require detailed costing. This article addresses the importance of and challenges associated with costing GS using a GS microcosting project in autism spectrum disorder as an illustrative example.
This is a preview of subscription content, log in via an institution to check access.
References
Buchanan J, Wordsworth S, Schuh A (2013) Issues surrounding the health economic evaluation of genomic technologies. Phamacogenomics 14:1833–1847. https://doi.org/10.2217/pgs.13.183
CADTH (2017) Guidelines for the economic evaluation of health technologies: Canada. 4th ed. CADTH, Ottawa
Jani M, Gavan S, Chinoy H, Dixon WG, Barton A, Harrison B, Moran A, Barton A, Payne K (2016) A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology 55:2131–2137. https://doi.org/10.1093/rheumatology/kew292
Jegathisawaran J, Tsiplova K, Marshall CR, Stavropoulos DJ, Pereira S, Thiruvahindrapuram, B, Ungar WJ (2018) A microcosting and cost-consequence analysis of genomic testing strategies (including trios) in austim spectrum disorder: an update. http://lab.research.sickkids.ca/task/reports-theses/. Accessed 14 Feb 2019
Phillips KA, Pletcher MJ, Ladabaum U (2015) Is the “$1000 genome” really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care 23:373–379. https://doi.org/10.3233/THC-150900
Schwarze K, Buchanan J, Taylor JC, Wordsworth S (2018) Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med 20:1122–1130. https://doi.org/10.1038/gim.2017.247
Tsiplova K, Zur RM, Ungar WJ, Marshall CR, Stavropoulos DJ, Pereira SL, Merico D, Young EJ, Sung WWL, Scherer SW (2016) A microcosting and cost-consequence analysis of genomic testing strategies in autism spectrum disorder. http://lab.research.sickkids.ca/task/reports-theses/. Accessed 18 May 2016
Tsiplova K, Zur RM, Marshall CR, Stavropoulos DJ, Pereira SL, Merico D, Young EJ, Sung WWL, Scherer SW, Ungar WJ (2017) A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med 19:1268–1275. https://doi.org/10.1038/gim.2017.47
Weymann D, Dragojlovic N, Pollard S, Regier DA (2019) Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges. J Community Genet:1–10. https://doi.org/10.1007/s12687-019-00428-5
Acknowledgments
We wish to thank the following individuals for their contributions: Christian R. Marshall, PhD, Associate Director, Genome Diagnostics, Department of Paediatric Laboratory Medicine, Dimitri J. Stavropoulos, PhD, Co-Director, Cytogenetics, Department of Paediatric Laboratory Medicine, Sergio L. Pereira, PhD, Research Core Manager, The Centre for Applied Genomics, Program in Genetics and Genome Biology, Bhooma Thiruvahindrapuram, MSc, Facility Manger, Scientific Lead, The Centre for Applied Genomics and Stephanie Luca, MA, PMP, Clinical Research Project Coordinator.
Funding
The research related to the manuscript was supported by a Large-Scale Applied Research Project grant from Genome Canada and the Ontario Genomics Institute and a grant-in-aid from the SickKids Centre for Genetic Medicine. Wendy J. Ungar is supported by a Canada Research Chair in Economic Evaluation and Technology Assessment in Child Health.
Author information
Authors and Affiliations
Contributions
Wendy J. Ungar contributed to the study conceptualization and funding acquisition. The first draft of the manuscript was written by Jathishinie Jegathisawaran and all authors reviewed and edited versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
The authors declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jegathisawaran, J., Tsiplova, K., Hayeems, R. et al. Determining accurate costs for genomic sequencing technologies—a necessary prerequisite. J Community Genet 11, 235–238 (2020). https://doi.org/10.1007/s12687-019-00442-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12687-019-00442-7